Exploring Undiscovered Gems in Europe This July 2025

Operations: The company’s primary revenue streams include professional intermediation contributing €1.11 billion and stock exchange online activities generating €74.37 million, while holdings contribute €5.40 million. The net profit margin is a critical metric to observe, reflecting the company’s efficiency in converting revenue into actual profit after all expenses are accounted for.

VIL, a modest player in the financial sector, has shown resilience with its debt to equity ratio dropping from 98.3% to 63% over five years. Its earnings growth of 23.1% outpaced the industry average of 12%, highlighting strong performance potential. The company is trading at a discount, approximately 15.9% below its estimated fair value, suggesting undervaluation opportunities for investors. Despite insufficient data on interest coverage by EBIT, VIL’s high-quality earnings and positive free cash flow provide confidence in its financial health and operational efficiency as it navigates the capital markets landscape effectively.

ENXTPA:VIL Debt to Equity as at Jul 2025

Simply Wall St Value Rating: ★★★★★☆

Overview: Medartis Holding AG is a medical device company specializing in the development, manufacturing, and sales of implant solutions on a global scale with a market capitalization of CHF978.12 million.

Operations: Medartis generates revenue primarily from its medical products segment, amounting to CHF224.83 million. The company has a market capitalization of CHF978.12 million.

Medartis, a nimble player in the medical device arena, is making strides with strategic moves like the Keri Touch launch and a 51% acquisition of NeoOrtho. Despite facing integration challenges, Medartis’ earnings surged 470% last year, outpacing industry growth of 34%. The company’s debt-to-equity ratio rose from 0.01% to 35.6% over five years but remains manageable given its cash surplus over total debt. Analysts forecast annual revenue growth of 13.6%, with profit margins potentially climbing from 1.6% to 7.9%. With earnings projected at CHF26M by May 2028 and a price target of CHF91, there’s room for optimism amidst execution risks in U.S strategies.

SWX:MED Earnings and Revenue Growth as at Jul 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTPA:MLZAM ENXTPA:VIL and SWX:MED.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com